The relationship between glucose metabolism, metabolic syndrome, and bone-specific alkaline phosphatase: A structural equation modeling approach. by Cheung, BMY et al.
Title
The relationship between glucose metabolism, metabolic
syndrome, and bone-specific alkaline phosphatase: A structural
equation modeling approach.
Author(s) Cheung, CL; Tan, KCB; Lam, KSL; Cheung, BMY
Citation Journal of Clinical Endocrinology and Metabolism, 2013, v. 98 n.9, p. 3856-3863
Issued Date 2013-08-20
URL http://hdl.handle.net/10722/185985
Rights Creative Commons: Attribution 3.0 Hong Kong License
The relationship between glucose metabolism, metabolic 
syndrome, and bone-specific alkaline phosphatase: A 
structural equation modeling approach 
 
Running title: Insulin resistance and alkaline phosphatase 
 
1
Ching-Lung Cheung, PhD,  
2, 3
Kathryn CB Tan, MD, FRCP,  
2, 3
Karen SL Lam, MD, FRCP, FRACP, 
1, 3
Bernard MY Cheung, PhD, FRCP 
 
1
Division of Clinical Pharmacology and Therapeutics, 
2
Division of Endocrinology 
and Metabolism, 
3
Research Centre of Heart, Brain, Hormone and Healthy Aging, 
Department of Medicine, Li Ka Shing Faculty of Medicine, 
The University of Hong Kong, Pokfulam, Hong Kong, China 
 
Correspondence: 
Bernard MY Cheung, 
University Department of Medicine, 
*Manuscript (MUST INCLUDE TITLE PAGE AND ABSTRACT)
Click here to download Manuscript (MUST INCLUDE TITLE PAGE AND ABSTRACT): 2013Manuscript_JCEM2.doc 
Queen Mary Hospital, 
102 Pokfulam Road, Hong Kong 
Email: mycheung@hku.hk 
Tel: +85222554347 
Fax: +85228186474 
 
Disclosure summary: The authors have nothing to disclose. 
 
Words count:  
Abstract: 239; Main text: 3195 
 
Number of tables: 3 
Number of figure (in black and white): 1 
 
 
 
 
 
 
Abstract 
Context: Serum alkaline phosphatase plays a role in vascular calcification. It is found 
in various tissues, whereas bone-specific alkaline phosphatase (BAP) more 
specifically reflects mineral metabolism. The relationship of serum alkaline 
phosphatase (total and bone-specific) with diabetes and metabolic syndrome, two 
major risk factors of vascular calcification, is largely unknown. 
Objective: We aimed to investigate the relationships between glucose metabolism, 
components of MetS, and alkaline phosphatase. 
Design: This was a cross-sectional study. 
Setting: Nationally representative sample of the US population in 1999-2004. 
Participants: 3,773 non-diabetic participants of the National Health and Nutrition 
Examination Survey 1999-2004. 
Main Outcome Measures: Serum BAP and total alkaline phosphatase. 
Results: In multivariable linear regression, HOMA2-IR (β=0.068), HOMA2-B 
(β=0.081), insulin (β=0.065), mean arterial pressure (β=0.15), and HDL-cholesterol 
(β=0.209) were positively associated with BAP, whereas HOMA2-IS (β=-0.065) was 
negatively associated with BAP. On the other hand, only mean arterial pressure and 
HDL-cholesterol were significantly associated with total alkaline phosphatase. 
Moreover, structural equation model revealed that hypertension, low HDL, and 
insulin resistance had significant direct effects on serum BAP levels, whereas obesity 
and inflammation might have indirect effects on serum BAP levels. The overall model 
showed very good fit to the data (comparative fit index = 0.995, root mean square 
error of approximation = 0.037, and standardized root mean square residual = 0.006). 
Conclusion: Glucose metabolism and MetS are significantly related to serum BAP 
levels. How BAP mediates vascular calcification in diabetes and MetS warrants 
further studies. 
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Introduction 
Diabetes mellitus and metabolic syndrome (MetS) are major risk factors of vascular 
calcification (1). Patients with diabetes have more extensive coronary artery disease, 
and atherosclerotic plaque morphology in diabetic patients may be predisposed to 
rupture and thrombosis (2). Among patients with acute coronary syndromes, patients 
with co-morbidity diabetes or MetS have a greater lesion length, plaque burden, 
necrotic core, and calcium content among nonculprit lesions (3). Moreover, higher 
incidence and progression of coronary artery calcium have also been demonstrated in 
subjects with MetS or diabetes (4). However, the underlying mechanism is poorly 
understood. 
 
Extracellular pyrophosphate and alkaline phosphatase have been identified as key 
molecules in vascular calcification (1). Pyrophosphate is a potent inhibitor of tissue 
mineralization and vascular calcification (5). Pyrophosphate is produced by an 
enzyme, ectonucleotide pyrophosphatasephosphodiesterease 1 (NPP1), which is 
located in the cell membrane. It is then transported across the cell membrane to the 
extracellular matrix by the progressive ankylosis protein (ANK). Bone-specific 
alkaline phosphatase (BAP) hydrolyzes pyrophosphate and so promotes tissue 
mineralization (6-7). Knockout mice deficient in NPP1 and ANK have increased 
aortic calcification (5) and medial calcification (8), respectively. On the other hand, 
blocking the hydrolyzing action of BAP ameliorated the calcification in vascular 
smooth muscle cells from NPP1- and ANK-deficient mice (7). Thus, alkaline 
phosphatase has a critical role in calcification, and it has been extensively used as a 
marker of calcification (6-7) and exploited as therapeutic target of vascular 
calcification (7, 9). Previous studies also showed that serum alkaline phosphatase is a 
predictor of mortality (10-11) and cardiovascular events (11). 
 
A number of studies have investigated the association between serum alkaline 
phosphatase and diabetes/MetS owing to its role as a hepatobiliary marker. However, 
serum alkaline phosphatase consists of several alkaline phosphatase isoforms from 
various tissues, such as liver, bone, and kidney, with a large proportion are derived 
from liver and bone. Previous studies showed that BAP reflects mineral metabolism 
with a higher sensitivity and specificity than total alkaline phosphatase (12). 
Therefore in the current study, we aimed to evaluate the relationship between glucose 
metabolism, metabolic syndrome, alkaline phosphatase, and BAP in a large 
nationally-representative population.  
 
Materials and Methods 
The current study utilized data from National Health and Nutrition Examination 
Survey (NHANES) 1999–2004 (13). The NHANES included a stratified multistage 
probability sample which represented the civilian non-institutionalized U.S. 
population. Selection was based on counties, blocks, households, and individuals 
within households. It also included non-Hispanic blacks and Mexican-Americans to 
provide an adequate estimate of these ethic groups. Participants were required to sign 
a consent form before their participation, and ethical approval was obtained from the 
Human Subjects Committee of the U.S. Department of Health and Human Services. 
 
Our analysis included non-pregnant participants aged 20 or above whose BAP and 
fasting glucose levels were available (n=5,057). We excluded participants with 
missing data in the multivariable models or without weight in the complex sampling 
model (n=757) and participants with diabetes (n=527, defined as a plasma glucose 
level ≥126 mg/dl [7.0 mmol/L] after fasting for a minimum of 8 hours, a 
glycohemoglobin (HbA1C) value ≥6.5%, self-reported diabetes or self-reported 
current use of oral hypoglycemic medication or insulin). After exclusion, 3,773 
participants were included in the analysis. 
 
BAP and total alkaline phosphatase 
Serum BAP was measured using the Hybritech Tandem-MP ostase 
immunoenzymetric assay (1999-2001, 2003-2004) and the Beckman access ostase 
assay (2002). Since there were two methods in measuring BAP, therefore NHANES 
recommends the following regression equation to convert the Hybritech assay values 
to the Beckman assay values: Beckman assay serum BAP = exp(-0.5326*1.1139*x - 
0.7963*(max(0,x -4.5151)) + 0.9660*(max(0, x-4.9030)), where x = log(Hybritech 
assay serum BAP).This conversion was used in the present analysis. 
 
Serum total AP was measured as a routine laboratory blood parameter using Hitachi 
Model 704 multichannel analyzer in NHANES 1999–2000 and Beckman Synchron 
LX20 in NHANES 2003–2004. In NHANES 2001–2002, they were measured by 
either Hitachi Model 704 multichannel analyzer or Beckman Synchron LX20, and the 
reported values had been adjusted by regression equations to allow comparison across 
the two methods. 
 
Indices of glucose metabolism 
Serum insulin, plasma glucose, and HbA1C were measured at the Diabetes Diagnostic 
Laboratory, University of Missouri–Columbia. Plasma glucose and serum insulin 
were measured from fasting blood samples using hexokinase enzymatic method and 
radioimmunoassay, respectively. HbA1C was measured using Primus CLC330 and 
Primus CLC 385 analyzers (Primus Corporation, Kansas City, MO). The updated 
homeostasis model assessment (HOMA2) is more accurate than the original HOMA1, 
therefore Homeostasis model assessment calculator (14) was used to calculate the 
HOMA2 beta cell function (%B), insulin sensitivity (%S), and hepatic insulin 
resistance (IR).  
 
Components of MetS 
Lipids (total cholesterol, HDL-cholesterol, triglycerides) were measured 
enzymatically using Hitachi 704 Analyzer at the lipoprotein analytical laboratory, 
Johns Hopkins University School of Medicine. Seated systolic and diastolic blood 
pressures (mm/Hg) were measured using a mercury sphygmomanometer according to 
the American Heart Association and Seventh Joint National Committee 
recommendations. Mean arterial pressure (MAP, mm/Hg) was calculated as 2/3 
diastolic blood pressure + 1/3 systolic blood pressure.  
 
Independent variables 
Age (years), gender (male/female), race/ethnicity (Hispanics, non-Hispanic white, 
non-Hispanic Black, others), smoking status (current/ former/ non-smokers), alcohol 
use (drinkers/ non-drinkers), level of education (< high-school, high-school, > 
high-school), and physical activity (active/ sedentary) were assessed using a 
questionnaire. We used same definition for never, current and former smokers that is 
used in the National Health Interview Surveys (NHIS) conducted by Center for 
Disease Control. Individuals who had not smoked more than 100 cigarettes in their 
lifetime were considered non-smokers; those who had smoked more than 100 
cigarettes in their lifetime were considered former smokers if they answered 
negatively to the question “Do you smoke now?” and current smokers if they 
answered affirmatively. Individuals who had 12 alcohol drinks or more per year were 
considered as drinkers. Participants who reported doing moderate or vigorous activity 
for at least 10 minutes over the past 30 days on the Physical Activity Questionnaire 
were considered to be physically active. Body mass index (BMI, kg/m
2
) was 
calculated as weight in kilograms divided by height in meters squared. However, as 
BMI is highly correlated with waist circumference (r>0.8), we only included waist 
circumference (a component of MetS) as the independent variable to avoid 
collinearity. C-reactive protein (CRP, mg/dL), gamma-glutamyl transpeptidase (GGT, 
U/L), aspartate aminotransferase (AST, U/L), alanine transaminase (ALT, U/L), 
N-terminal telopeptides, and fatty liver index (15) were also included as independent 
variables. Fatty liver index was derived using the equation: FLI = (e 
0.953*loge (triglycerides) 
+ 0.139*BMI + 0.718*loge (ggt) + 0.053*waist circumference - 15.745
) / (1 + e 
0.953*loge (triglycerides) + 0.139*BMI + 
0.718*loge (ggt) + 0.053*waist circumference - 15.745
) * 100. Details regarding the measurement of 
the independent variables are available at the NHANES website (13).  
 
Statistical analyses 
Glycemic traits and components of MetS were analyzed as continuous and quartile 
variables. Multivariable linear regression was used to evaluate the association when 
glycemic traits and components of MetS were modeled as continuous variables. 
Estimated mean and 95% CI of BAP or tissue non-specific alkaline phosphatase for 
each quartile were calculated using ANCOVA in a general linear model, and linear 
trend P was obtained using contrast coefficients for linear trend analysis. Structural 
equation modeling (SEM) was used to estimate the model goodness-of-fit and 
directional estimates between variables. The predefined model used in the current 
study was modified from an existing model of MetS from literature.(16) The global 
Goodness of Fit Index for the SEM included the comparative fit index (CFI), root 
mean square error of approximation (RMSEA), and standardized root mean square 
residual (SRMR). These indices are less sensitive to sample size and complexity than 
χ2 test for evaluating model fit (17). Values for the CFI of ≥0.90 and ≥0.95 indicate 
acceptable and good fit, respectively (18). Values for the RMSEA values of ≤0.06 
represent good fit while values >0.10 represent unacceptable fit (18). A SRMR ≤0.08 
and <0.10 represent good and acceptable fit, respectively (18). SEM was carried out 
using R package “lavaan.survey” that performs SEM while taking account of the 
complex sampling of NHANES data. Variables with skewed distributions were 
log-transformed before analysis. Sample weights that account for the unequal 
probabilities of selection, oversampling, and non-response were applied for all 
analyses using complex sampling module in SPSS version 18.0 software (SPSS Inc, 
Chicago, IL). All values presented are weighted to represent the U.S. civilian 
population.  
 
Results 
Table 1 shows the sex-stratified characteristics of the 3,773 NHANES 1999-2004 
participants who were free from diabetes. Women were older, more likely to be 
non-Hispanic white, non-smokers., non-active drinkers and had lower physical 
activity. They had higher HDL-cholesterol levels, CRP, HOMA2-IS, and HOMA2-B. 
Conversely they had lower waist circumference, BAP, total alkaline phosphatase, 
triglyceride levels, MAP, ALT, AST, GGT, HbA1C, fasting glucose levels, insulin 
concentrations, and HOMA2-IR. 
 
Table 2 shows the association between glycemic traits and alkaline phosphatase. After 
adjustment of age, race/ethnicity, education, smoking, drinking, physical activity , and 
waist circumference in model 1, HOMA2-IR, HOMA2-B, fasting glucose, and insulin 
were positively associated with BAP, while HOMA2-IS was negatively associated 
with BAP (P<0.05). After further adjustment of metabolic risk factors (CRP, total 
cholesterol, AST, ALT, GGT, triglycerides, HDL-cholesterol, and MAP) in model 2, 
the association between BAP and fasting glucose became insignificant. Similar results 
were obtained when urinary N-terminal telopeptides and fatty liver index were 
adjusted in model 3. On the other hand, three indices (HOMA2-IR, HOMA2-B, and 
insulin) and HOMA2-IS were positively and negatively associated with tissue 
non-specific alkaline phosphatase in model 1, respectively. All associations became 
insignificant after further adjustment in models 2 and 3. Similar results were obtained 
when glycemic traits were categorized as quartiles (Supplementary Table 1). 
 
Table 3 shows the association between components of MetS and alkaline phosphatase. 
MAP and HDL-cholesterol showed significant association with BAP, while waist 
circumference and triglycerides showed a trend toward significant association with 
BAP (0.05 < P < 0.1). On the other hand, MAP and HDL-cholesterol showed 
significant association with tissue non-specific alkaline phosphatase, while no 
association was observed with waist circumference and triglycerides. Similar results 
were obtained when components of MetS were categorized as quartiles 
(Supplementary Table 2). 
 
Figure 1 illustrates our hypothesized relationships between BAP, inflammation, and 
components of MetS. All latent variables (denoted by oval circle) were adjusted for 
age, gender, race/ethnicity, drinking, smoking, and physical activity. As expected, 
obesity has direct association with hypertension, inflammation, and insulin resistance; 
inflammation has direct association with insulin resistance; insulin resistance has 
direct association with vascular calcification and dyslipidemia; and dyslipidemia and 
hypertension have direct association with vascular calcification. All of the 
standardized regression coefficients shown in the figure were statistically significant 
(P ≤0.001). The CFI was 0.995 (value >0.95 indicates good fit), RMSEA was 0.037 
(value <0.06 indicates good fit), and SRMR was 0.006 (value <0.08 indicates good 
fit), these fit indices consistently indicate that our hypothesized model is a good fitting 
model.  
 
Discussions 
The associations and inter-relationships between insulin resistance, components of 
MetS, and BAP were unraveled in the current study of the US-population using 
structural equation modeling in addition to multivariable linear regression. Although 
tissue non-specific alkaline phosphatase is known to correlate with insulin resistance 
and metabolic syndrome owing to its role as a hepatobiliary marker, our study clearly 
shows that both hyperinsulinemia, insulin resistance, and MetS are in fact more 
strongly associated with BAP.  
 
Our study excluded participants with diabetes allowing us to study the relationship of 
hyperinsulinemia or insulin resistance with BAP, without the confounding effect of 
significant hyperglycaemia. Note that the direct effect of insulin on osteoblasts is a 
stimulation of osteoblast proliferation & differentiation, and an increase in BAP 
activity in vitro (19). On the other hand, streptozotocin-induced insulin deficiency 
(type 1 diabetes) in rats is associated with reduced BAP which is reversed by insulin 
therapy (20). In humans, osteopenia is observed in type 1 diabetic patients even with 
good control. On the other hand, high glucose per se has deleterious effect on 
osteoblast function in vitro (rat primary osteoblast cell culture) and decreases BAP 
secreted (21). Only subjects with poorly controlled type 2 diabetes are at risk of 
osteoporosis. 
 
Our study sheds light on the mechanism of elevated BAP. While insulin resistance is 
known to be a risk factor for vascular calcification, the mechanism is not completely 
understood. In the current study, we showed that multiple HOMA2 indices and insulin 
levels are robustly associated with BAP rather than total alkaline phosphatase. 
Although total alkaline phosphatase could be elevated due to obesity, insulin 
resistance, fatty liver, and hepatosteatosis, no significant association was observed 
between HOMA2-IR and total alkaline phosphatase in the fully adjusted model. This 
may be explained by the fact that other liver markers included in the model were more 
specific to liver dysfunction; ALT, AST, and GGT also showed significant 
associations (P<0.05) with HOMA2-IR in the fully adjusted model. When ALT, AST, 
and GGT were removed from the fully adjusted model, the association between 
alkaline phosphatase and HOMA2-IR became significant (P = 0.015). On the other 
hand, elevated BAP could be due to the presence of fatty liver. However, further 
adjustment for fatty liver index (15), a validated marker of fatty liver, did not change 
the association of HOMA2-IR, HOMA2-IS, HOMA2-B, and insulin with BAP (Table 
2), suggesting that the association was independent of fatty liver. In addition, our 
study also showed that BAP is associated with multiple components of MetS, which 
suggested that hyperinsulinemia, insulin resistance, and MetS could lead to serum 
BAP elevation. In line with our previous studies (22-23), serum CRP was significantly 
associated with alkaline phosphatase in the current study, while no association was 
observed with BAP (P > 0.5; data not shown). These observations further suggested 
that although total alkaline phosphatase and BAP are strongly correlated, the causes of 
elevation of total alkaline phosphatase and BAP could be different. 
 
There have only been a few studies of BAP with insulin resistance and MetS. In 
agreement with a cross-sectional study carried out in 328 type 2 diabetes patients, we 
also observed no significant association between BAP and fasting plasma glucose and 
HbA1c (24). In a study of 54 healthy postmenopausal women, there was no 
correlation between BAP and any components of MetS (25), which could be due to 
the small sample size. 
 
Serum alkaline phosphatase is routinely measured clinically, while BAP is not. 
Therefore, most epidemiological studies examined the association of serum alkaline 
phosphatase with mortality and cardiovascular diseases. Among 4,115 participants of 
the Cholesterol And Recurrent Events study, alkaline phosphatase was associated with 
all-cause mortality. This finding was subsequently replicated using NHANES III data, 
with significant association being observed between alkaline phosphatase and 
all-cause and cardiovascular mortality (10). Similar results are observed in patients 
with maintenance hemodialysis (26) and acute stroke (27). In a retrospective study 
including 10,743 outpatients, serum alkaline phosphatase was robustly associated 
with mortality (including cardiovascular mortality) and cardiovascular related 
hospitalization (28). In addition to mortality, serum alkaline phosphatase has been 
reported to be associated with multiple cardiovascular diseases, such as stroke 
incidence (29), coronary artery calcification score (30), myocardial infarction, stent 
thrombosis, major adverse cardiac event, and coronary calcification (11). Our earlier 
study also showed that elevated alkaline phosphatase is associated with peripheral 
arterial disease (31). A few studies examined the role of BAP in mortality and 
cardiovascular diseases. In 130 osteoporotic patients, serum BAP was significantly 
higher in those with vascular calcification than those without (32). In a prospective 
study carried out in 800 dialysis patients, serum BAP was robustly associated with 
cardiovascular and non-cardiovascular mortality, and the effect size was much 
stronger than that of serum total alkaline phosphatase (33). Altogether, these studies 
suggested that alkaline phosphatase is an important predictor of mortality and 
cardiovascular events, while our current study provided evidence that BAP may be the 
link between insulin resistance and vascular calcification, cardiovascular diseases, or 
even mortality. Future studies on clinical outcomes should measure BAP in addition 
to total alkaline phosphatase (11). 
BAP is known as a bone formation marker. Our previous study showed that genetic 
variation in ALPL gene was associated with hip geometry and bone mineral density in 
1,513 Framingham Offspring Cohort participants (34). Therefore the associations 
observed in the current study could reflect difference in bone turnover. We then 
further adjusted for another bone turnover marker, urinary N-terminal telopeptides, in 
the logistic regression model (Table 2). Further adjustment for urinary N-terminal 
telopeptides attenuated the estimates but the associations remained statistically 
significant. These findings suggest that at least part of the association between 
glycemic traits and BAP is independent of bone turnover. Similarly, BAP may also be 
associated with growth. We then performed sensitivity analysis by excluding 
participants aged <25, and the results were essentially similar to the results before the 
exclusion (Supplementary Table 3). Future study is required to confirm our findings. 
The association of MetS with osteoporosis is controversial, with MetS was reported to 
be associated with higher BMD (35) and lower BMD (36). In previous study, blood 
pressure was shown to be negatively associated with bone mineral density (36). 
However, blood pressure was found to be positively associated with BAP in the 
current study. It should also be noted that, although BAP is mainly expressed in 
osteoblast, it is also expressed in other cells, such as B-cell (37) and vascular smooth 
muscle cells (38). Therefore, serum BAP could also be contributed by other cells, 
although it is expected to be contributed predominantly by osteoblasts. 
 
Population studies have shown that diabetes is preventable or even reversible. 
Therefore, identification of biomarkers may have the potential for early diagnosis of 
insulin resistance and hence prevention of diabetes (39-40). In this study, we showed 
that serum BAP concentration is associated with several metabolic traits, therefore 
BAP could potential be used as a biomarker. Future studies are required to examine 
whether addition of BAP as a predictive biomarker could enhance the performance of 
existing prevention strategies such as increased physical activity, healthy diet, and 
early treatment of hyperglycemia (39-40).  
 
Our study has several strengths. The study population is large, multiethnic, 
nationally-representative, and well-characterized with data on multiple risk factors 
and confounders. The findings were shown to be robust in multiple statistical tests. 
Nevertheless, there are limitations. First, cross-sectional data cannot prove causality. 
Second, although the model in the current study showed a good fit in SEM, this may 
not be the only plausible model since the mechanisms underlying metabolic risk 
factors is complex. Future studies incorporating evidence from laboratory and human 
studies are required to investigate the mechanism in detail. Third, HOMA2 indices are 
only surrogate markers, for example, HOMA2-IR is a surrogate marker of hepatic 
insulin resistance; and these indices are strongly correlated with insulin levels. It is 
unclear whether insulin resistance, insulin levels, or both leads to increased BAP. 
Future studies using euglycemic hyperinsulinemic and hyperglycemic clamp 
techniques are required to confirm our findings. Fourth, as aforementioned, the 
regulation of BAP is complex, therefore the results should be interpreted with caution. 
 
In conclusion, our study provides a possible mechanism for the increased vascular 
calcification in subjects with increased insulin resistance such as MetS or type 2 
diabetes. Future studies are required to examine whether improving insulin resistance 
and MetS could reduce the expression of BAP and the risk of vascular calcification 
and cardiovascular disease. 
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Table 1. Characteristics of the study population (NHANES 1999-2004). 
  
Total (n=3,773) 
 
Men (n=1,932) 
 
Women (n=1,841) 
  
    % (95% CI)   % (95% CI)   % (95% CI)   P-value 
% 
    
49.6 (48.4-50.8) 
 
50.4 (49.2-51.6) 
 
NA 
Smoking (%) 
           
never 
 
50.7 (47.9-53.6) 
 
44.6 (41.3-48) 
 
56.7 (53.2-60.1) 
 
<0.001 
former 
 
23.3 (21.3-25.4) 
 
26.3 (24.1-28.6) 
 
20.3 (17.7-23.2) 
 
<0.001 
current 
 
26 (23.8-28.4) 
 
29 (26.2-32.1) 
 
23 (20.7-25.6) 
 
<0.001 
Active drinker (%) 
 
75 (71.2-78.4) 
 
84.3 (80.5-87.6) 
 
65.8 (61-70.3) 
 
<0.001 
Race/ethnicity (%) 
           
Mexican American 
 
12.7 (9.8-16.4) 
 
13.6 (10.5-17.4) 
 
11.8 (8.8-15.7) 
 
0.101 
Non-Hispanic White 
 
73.6 (69.9-77) 
 
72.5 (68.5-76.2) 
 
74.7 (71-78) 
 
0.04 
Non-Hispanic Black 
 
10 (8.1-12.3) 
 
9.7 (7.8-12.1) 
 
10.2 (8.1-12.8) 
 
0.516 
Others 
 
3.7 (2.8-5) 
 
4.2 (3-5.9) 
 
3.3 (2.1-5) 
 
0.324 
Education (%) 
           
< High school 
 
18.5 (16.9-20.2) 
 
18.8 (16.5-21.4) 
 
18.2 (16.3-20.2) 
 
0.667 
High school 
 
26.3 (23.9-28.9) 
 
27.6 (24.8-30.5) 
 
25.1 (22.2-28.3) 
 
0.147 
> High school 
 
55.1 (52.2-58) 
 
53.6 (50.2-56.9) 
 
56.7 (53-60.3) 
 
0.12 
Had moderate or vigorous 
activity (%)  
65.9 (63.5-68.2) 
 
67.5 (64.6-70.3) 
 
64.2 (61.4-66.9) 
 
0.038 
Age (yr) 
 
39.94  (39.03-40.88) 
 
38.84  (37.93-39.78) 
 
41.05  (39.95-42.18) 
 
<0.001 
BMI (m/kg
2
) 
 
26.99  (26.75-27.23) 
 
27.09  (26.82-27.36) 
 
26.90  (26.53-27.26) 
 
0.357 
Waist circumference (cm) 
 
93.35  (92.73-93.99) 
 
96.92  (96.12-97.75) 
 
89.97  (89.1-90.87) 
 
<0.001 
Bone-specific Alkaline 
phosphatase(ug/L)  
13.76  (13.45-14.08) 
 
14.96  (14.57-15.35) 
 
12.68  (12.3-13.07) 
 
<0.001 
ALP (U/L) 
 
67.05  (65.89-68.22) 
 
70.36  (68.8-71.94) 
 
63.94  (62.75-65.16) 
 
<0.001 
ALT (U/L) 
 
22.50  (22.15-22.86) 
 
27.25  (26.52-27.98) 
 
18.65  (18.25-19.05) 
 
<0.001 
AST (U/L) 
 
22.86  (22.51-23.2) 
 
25.10  (24.58-25.63) 
 
20.84  (20.46-21.23) 
 
<0.001 
GGT (U/L) 
 
21.67  (21.09-22.26) 
 
26.95  (25.98-27.96) 
 
17.48  (16.93-18.06) 
 
<0.001 
C-reactive protein(mg/dL) 
 
0.18  (0.17-0.19) 
 
0.15  (0.14-0.16) 
 
0.22  (0.21-0.24) 
 
<0.001 
Total cholesterol (mg/dL) 
 
196.47  (194.4-198.52) 
 
196.34  (193.55-199.11) 
 
196.61  (194.4-198.79) 
 
0.847 
Triglycerides (mg/dL) 
 
115.50  (112.05-119.07) 
 
124.17  (118.77-129.81) 
 
107.60  (104.35-110.92) 
 
<0.001 
HDL-cholesterol (mg/dL) 
 
49.75  (49-50.5) 
 
44.99  (44.1-45.89) 
 
54.92  (53.91-55.92) 
 
<0.001 
Mean arterial pressure 
(mm/Hg)  
87.76  (87.22-88.31) 
 
89.23  (88.63-89.85) 
 
86.34  (85.59-87.08) 
 
<0.001 
Glycohemoglobin (%) 
 
5.23  (5.21-5.26) 
 
5.25  (5.22-5.28) 
 
5.22  (5.19-5.24) 
 
0.006 
Glucose, plasma (mg/dL) 
 
94.54  (93.99-95.1) 
 
96.38  (95.76-97.03) 
 
92.77  (92.15-93.39) 
 
<0.001 
Insulin (uU/mL) 
 
8.87  (8.59-9.17) 
 
9.21  (8.84-9.59) 
 
8.55  (8.24-8.88) 
 
0.001 
HOMA2-IR 
 
1.00  (0.97-1.04) 
 
1.05  (1.01-1.09) 
 
0.96  (0.93-1) 
 
<0.001 
HOMA2-IS (%) 
 
99.52  (96.32-102.83) 
 
95.50  (91.69-99.47) 
 
103.63  (99.79-107.65) 
 
<0.001 
HOMA2-B (%)   86.28  (84.63-87.98)   85.15  (83.2-87.16)   87.42  (85.39-89.47)   0.049 
Data are geometric means (95% CI). All values presented are weighted to represent 
the U.S. civilian population, 1999-2004. P-value represents differences in means or 
proportions, using ANOVA or χ2 test. 
 
Table 2. Association between glycemic traits and alkaline phosphatase (bone-specific or total) in NHANES 1999-2004 
 
Glycemic traits 
Model 1 (N=3,773) Model 2 (N=3,773) Model 3 (N=3,009)* 
 Estimate 95% CI P-value Estimate 95% CI P-value Estimate 95% CI P-value 
B
o
n
e-
sp
ec
if
ic
 a
lk
al
in
e 
p
h
o
sp
h
at
as
e 
HOMA-IR 0.109 (0.079-0.138) <0.001 0.068 (0.038-0.097) <0.001 0.044 (0.008-0.08) 0.018 
HOMA-IS -0.107 (-0.137--0.077) <0.001 -0.065 (-0.095--0.035) <0.001 -0.041 (-0.079--0.004) 0.031 
HOMA-b 0.134 (0.088-0.18) <0.001 0.081 (0.038-0.125) <0.001 0.054 (0.009-0.1) 0.02 
Fasting glucose (mg/dL) 0.202 (0.038-0.366) 0.017 0.072 (-0.082-0.227) 0.351 0.021 (-0.167-0.208) 0.823 
Insulin (uU/mL) 0.107 (0.077-0.136) <0.001 0.065 (0.035-0.095) <0.001 0.042 (0.005-0.078) 0.026 
HbA1C (%) 0.22 (-0.033-0.473) 0.087 0.13 (0.085-0.346) 0.229 0.109 (-0.142-0.36) 0.382 
T
o
ta
l 
al
k
al
in
e 
p
h
o
sp
h
at
as
e 
HOMA-IR 0.072 (0.048-0.096) <0.001 0.022 (-0.002-0.045) 0.071 -0.017 (-0.047-0.013) 0.259 
HOMA-IS -0.07 (-0.095--0.046) <0.001 -0.02 (-0.044-0.004) 0.098 0.02 (-0.011-0.051) 0.2 
HOMA-b 0.092 (0.055-0.13) <0.001 0.032 (-0.002-0.065) 0.065 -0.014 (-0.05-0.023) 0.457 
Fasting glucose (mg/dL) 0.089 (-0.05-0.228) 0.202 -0.031 (-0.166-0.103) 0.643 -0.077 (-0.242-0.089) 0.35 
Insulin (uU/mL) 0.07 (0.046-0.094) <0.001 0.02 (-0.004-0.043) 0.095 -0.019 (-0.049-0.011) 0.199 
HbA1C (%) 0.122 (-0.058-0.302) 0.179 0.004 (-0.157-0.164) 0.965 0.008 (-0.169-0.185) 0.93 
Model 1: Adjusted for age, race/ethnicity, education, smoking, drinking, physical activity, and waist circumference; Model 2: Further adjusted 
for AST, ALT, GGT, total cholesterol, triglycerides, HDL-cholesterol, mean arterial pressure, and CRP; Model 3: Further adjusted for fatty liver 
index and urinary N-terminal telopeptides, while waist circumference was removed from the model due to high correlation with fatty liver 
index. 
* Urinary N-telopeptides data was only available in NHANES 1999-2002. 
 
Table 3. Association between components of MetS and alkaline phosphatase (bone-specific or total) in NHANES 1999-2004 
Components of MetS 
Bone-specific alkaline phosphatase 
 
Total alkaline phosphatase 
Estimate 
95% CI 
P-value  Estimate 
95% CI 
P-value 
Lower limit Upper limit   Lower limit Upper limit 
Waist Circumferences (cm) -0.122 -0.244 0.001 0.052 
 
-0.049 -0.153 0.056 0.352 
Mean Arterial Pressure (mm/Hg) 0.15 0.041 0.259 0.008 
 
0.119 0.045 0.193 0.002 
HDL-cholesterol (mg/dL) -0.209 -0.272 -0.147 <0.001 
 
-0.167 -0.217 -0.117 <0.001 
Triglyceride (mg/dL) -0.041 -0.086 0.003 0.069   -0.025 -0.062 0.013 0.191 
Components of MetS simultaneously included in the model with further adjustment of age, race/ethnicity, education, smoking, drinking, 
physical activity, AST, ALT, GGT, total cholesterol, HOMA-IR, and CRP. 
 
Figure 1. Pre-defined structural equation model outlining relationships between 
insulin resistance, components of MetS, and BAP. 
 
 
Oval circle indicates latent variable that is not measured directly. Standardized 
regression coefficients are at the base of each arrow. *** P≤0.001. HDL level, 
inflammation, obesity, IR, hypertension, and BAP level were adjusted for age, gender, 
race/ethnicity, drinking, smoking, and physical activity in the structural equation 
model. 
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